Research partner marketplaceCode PEPTIDESDE
PeptideStat
Index
Research noteglp-1

Semaglutide vs Liraglutide: Wegovy/Ozempic vs Saxenda/Victoza Compared

Semaglutide vs liraglutide for weight loss and diabetes: weekly vs daily dosing, trial results, labels, side effects, half-life and practical tradeoffs.

Published
May 18, 2026
Last reviewed
May 18, 2026
Reading time
4 min read
By
PeptideStat Editorial Team
This article separates published evidence from commercial claims. It is educational, not medical advice.

Semaglutide and liraglutide are both GLP-1 receptor agonists, but they belong to different eras of obesity medicine.

Liraglutide came first. It is sold as Saxenda for weight management and Victoza for type 2 diabetes. Semaglutide came later, with weekly injectable products such as Wegovy and Ozempic. For most weight-loss searches, semaglutide is the stronger and more convenient option.

For broader approved-drug rankings, read best GLP-1 for weight loss.

Quick Comparison

QuestionSemaglutideLiraglutide
Drug classGLP-1 receptor agonistGLP-1 receptor agonist
Major brandsWegovy, Ozempic, RybelsusSaxenda, Victoza
Typical injection frequencyWeekly for Wegovy/Ozempic injectionsDaily for Saxenda/Victoza
Weight-loss edgeStronger average weight loss in direct obesity comparisonLower average weight loss, older track record
Best practical useMost people comparing modern GLP-1 weight-loss optionsWhen access, supply, cost or tolerability favors it

Why Semaglutide Usually Wins

The direct STEP 8 comparison found a large gap between semaglutide and liraglutide in adults with overweight or obesity. Semaglutide produced much larger average weight loss and is weekly, which also helps adherence for many people.

Evidence pointSemaglutideLiraglutideMeaning
Direct STEP 8 obesity trialAbout 15.8% average body-weight reductionAbout 6.4% average body-weight reductionSemaglutide had the clear weight-loss advantage.
Dosing rhythmWeekly injection for major injectable brandsDaily injectionWeekly is easier for many patients.
Half-life patternLong-actingShorter-actingThis is one reason dosing schedules differ.

When Liraglutide Can Still Make Sense

Liraglutide is not obsolete just because semaglutide is stronger on average. It can still be relevant when:

  • Insurance coverage favors Saxenda or Victoza.
  • Newer weekly drugs are unavailable.
  • A clinician wants an older daily option with a longer clinical history.
  • A patient prefers the ability to stop a shorter-acting daily drug quickly if side effects are a problem.

That said, for weight loss alone, the average efficacy gap is hard to ignore.

Side Effects

Both drugs share GLP-1 class effects:

  • Nausea.
  • Vomiting.
  • Diarrhea.
  • Constipation.
  • Reflux or abdominal discomfort.
  • Reduced appetite.
  • Injection-site reactions.

Serious warnings and contraindications come from each label. Do not assume that a lower average weight-loss drug is automatically safer. The right comparison is individual tolerability plus label risks.

Bottom Line

Semaglutide is usually the better weight-loss comparison because it is stronger on average and easier to take as a weekly injectable. Liraglutide remains a valid older GLP-1 option when access, coverage or clinician judgment points that way.

For the next comparison up, read semaglutide vs tirzepatide.

FAQ

Is semaglutide better than liraglutide for weight loss?

In direct obesity-trial data, semaglutide produced substantially more average weight loss than liraglutide.

Is Saxenda the same as Wegovy?

No. Saxenda is liraglutide, a daily GLP-1 injection. Wegovy is semaglutide, a longer-acting GLP-1 product used for weight management.

Why is liraglutide daily while semaglutide is weekly?

Semaglutide has a much longer half-life than liraglutide, which supports weekly dosing for injectable semaglutide products.

Does liraglutide still have a role?

Yes. It may matter when coverage, supply, tolerability or clinician preference points away from newer weekly agents.

Are side effects different?

The general GLP-1 side-effect pattern is similar, with gastrointestinal symptoms most common. Dose, titration and individual tolerance matter.

References

  1. Rubino DM, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity. JAMA.

  2. Novo Nordisk. Wegovy prescribing information.

  3. Novo Nordisk. Saxenda prescribing information.

  4. Novo Nordisk. Ozempic prescribing information.

Filed under

semaglutide vs liraglutidesemaglutideliraglutidesaxendawegovyglp-1 comparison

Continue in the database

Structured status, mechanism and evidence notes for compounds connected to this guide.

Liraglutide

Victoza, Saxenda

5/5
Weight lossApproved

Daily GLP-1 analog. Reduces appetite and improves glycemic control via the same incretin pathway as semaglutide.

DetailsGuide

Semaglutide

Ozempic, Wegovy, Rybelsus

5/5
Weight lossApproved

Mimics the incretin GLP-1, slowing gastric emptying and reducing appetite while improving insulin secretion.

DetailsGuide

Dulaglutide

Trulicity

5/5
Weight lossApproved

Dulaglutide is a long-acting GLP-1 receptor agonist that stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and reduces appetite.

DetailsGuide

Exenatide

Byetta, Bydureon, exendin-4

5/5
Weight lossApproved

Exenatide activates the GLP-1 receptor to increase glucose-dependent insulin secretion, suppress inappropriate glucagon release, and slow gastric emptying.

DetailsGuide

Glucagon

GlucaGen, Baqsimi, Gvoke

5/5
Metabolic healthApproved

Glucagon binds the hepatic glucagon receptor (GCGR), raising cyclic AMP to stimulate glycogenolysis and gluconeogenesis, which increases blood glucose as the body's main counter-regulatory hormone opposing insulin.

DetailsGuide

Work with the numbers

Open reconstitution, unit-conversion and accumulation tools with editable examples.

Peptide reconstitution calculatorCalculate concentration, draw volume and syringe units from vial strength and BAC water.Open toolPeptide accumulation calculatorModel repeated dosing schedules with half-life, interval, peak and trough estimates.Open toolPeptide unit converterConvert mg, mcg, optional IU and syringe units from one reconstituted vial setup.Open toolPeptide chemistry calculatorAnalyze sequence length, molecular weight, composition, charge, hydropathy and notation.Open tool

Prefilled calculator shortcuts

Open calculators with editable examples for compounds mentioned around this guide.

Liraglutide accumulation calculatorPrefills 13 hour half-life and 24 hour interval examples.Open prefilled toolSemaglutide reconstitution calculatorPrefills a 5 mg vial, 2 mL BAC water and editable dose fields.Open prefilled toolSemaglutide accumulation calculatorPrefills 168 hour half-life and 168 hour interval examples.Open prefilled toolSemaglutide unit converterPrefills 250 mcg with a 5 mg vial example.Open prefilled tool

Explore the wider category

Compare the broader evidence landscape before focusing on one compound.

Weight Loss Peptides

Compare weight loss peptides including GLP-1, GIP, amylin and triple-agonist compounds by approval status, mechanism, half-life and evidence score.

Read next

GLP-1 Pancreatitis Risk: What Labels, Trials and Symptoms ShowGLP-1 pancreatitis risk is real enough to appear in labels, but rare enough that trials and meta-analyses need careful interpretation.Ozempic Vision Loss and NAION: What Semaglutide Evidence ShowsSemaglutide and NAION is now a real pharmacovigilance topic, but the absolute risk appears low and the evidence is mostly observational.Orforglipron (Foundayo): Oral GLP-1 Pill Evidence, Label and LimitsOrforglipron is the oral small-molecule GLP-1 sold as Foundayo. It is not a peptide, but it matters for peptide readers because it changes the oral GLP-1 comparison.